New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 24, 2014
04:55 EDTCRME, CRME, ALR, ALR, GALE, GALE, BIND, BIND, AVNR, AVNR, OCRX, OCRX, ONVO, ONVO, OSIR, OSIR, SGNT, SGNT, SNTA, SNTA, CRIS, CRISJMP Securities to hold a conference
Healthcare Conference to be held in New York on June 24-25.
News For CRME;SNTA;SGNT;OSIR;ONVO;OCRX;AVNR;BIND;GALE;ALR;CRIS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 29, 2015
12:39 EDTSNTAFly Watch: Several names that may move following ASCO meeting
Subscribe for More Information
May 27, 2015
07:07 EDTGALEGalena announces publication of two abstracts at ASCO
Galena Biopharma announced two abstract publications at the American Society of Clinical Oncology, or ASCO, 2015 Annual Meeting. "The two abstracts published by ASCO provide meaningful advancements for both of our cancer immunotherapy programs, NeuVax and GALE-301," said Mark Schwartz, Ph.D., president and CEO. "The use of Leica's Bond Oracle HER2 IHC system ensures we have enrolled the specified HER2 1+/2+ patients for our Phase 3 NeuVax™ PRESENT trial and moves us further down the path of providing targeted, personalized medicine for these women. Meanwhile, the published preliminary data from our GALE-301 program is quite promising as it shows significant reduction of recurrences with our vaccine. We expect to present more mature data at a scientific conference this Fall, and we are currently evaluating the next steps to potentially advance GALE-301 into a randomized late-stage trial to prevent recurrence in ovarian and endometrial cancers."
May 26, 2015
07:30 EDTALRAlere should continue to be accumulated at current levels, says Canaccord
Canaccord recommended investors continue to accumulate shares of Alere given expectations for multiple expansion, management execution on core initiatives, and a deep commitment to quality. Canaccord reiterated its Buy rating and raised its price target to $60 from $56 on Alere shares.
May 21, 2015
16:41 EDTOSIROsiris evaluates the establishment of an international subsidiary
Osiris Therapeutics developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced that it is evaluating the establishment of an international, ex-U.S. subsidiary in recognition of its expanding research and commercial business operations. The company is currently evaluating different locations, including United Kingdom, Singapore and Switzerland.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use